Home | About the eMC | Help | Mobile
eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
Advanced search
Get Medicines Compendium UK app here

GlaxoSmithKline UK
Stockley Park West, Uxbridge, Middlesex, UB11 1BT
Telephone: +44 (0)800 221 441
Fax: +44 (0)208 990 4328
Medical Information e-mail: customercontactuk@gsk.com

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?
Summary of Product Characteristics last updated on the eMC: 05/03/2010
SPC Bactroban Nasal Ointment 2%

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 05/03/2010 and displayed until Current
Reasons for adding or updating:
  • Change to section 4.6 - Pregnancy and Lactation
  • Change to section 4.9 - Overdose
  • Change to section 10 date of revision of the text
  • Change to section 1 -Name of the Medicinal product
  • Change to section 4.4 - Special warnings and precautions for Use
Date of revision of text on the SPC:   01-Feb-2010
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company
Section 1 - Name changed 2% added

Section 4.4 - Whole section updated

Section 4.6 - Whole section updated

Section 4.9 - whole section updated

Section 10 - Date of approval added
Updated on 04/06/2008 and displayed until 05/03/2010
Reasons for adding or updating:
  • Change to section 9 - Date of first Authorisation/renewal of the Authorisation
  • Change to section 10 date of revision of the text
Date of revision of text on the SPC:   21-May-2008
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company
Section 9 - 21 May 2008

Section 10 - 21 May 2008
Updated on 19/05/2004 and displayed until 04/06/2008
Reasons for adding or updating:
  • Change to section 4.8 - Undesirable Effects
Updated on 17/05/2004 and displayed until 19/05/2004
Reasons for adding or updating:
  • Change to section 4.8 - Undesirable Effects
Updated on 10/03/2003 and displayed until 17/05/2004
Reasons for adding or updating:
  • Change to section 7 - Marketing Authorisation Holder
Updated on 12/11/2002 and displayed until 10/03/2003
Reasons for adding or updating:
  • Change to section 4.8 - Undesirable Effects
Updated on 26/09/2002 and displayed until 12/11/2002
Reasons for adding or updating:
  • Change to section 7 - Marketing Authorisation Holder
Updated on 29/07/2002 and displayed until 26/09/2002
Reasons for adding or updating:
  • Change to section 7 - Marketing Authorisation Holder
Updated on 05/08/2001 and displayed until 29/07/2002
Reasons for adding or updating:
  • Transferred from eMC version 1
Updated on 14/03/2000 and displayed until 05/08/2001
Reasons for adding or updating:
  • No reasons supplied
Updated on 06/09/1999 and displayed until 14/03/2000
Reasons for adding or updating:
  • No reasons supplied

Active Ingredients/Generics

 
  mupirocin calcium